INSM

Insmed has crossed from clinical-stage hope into a commercial-stage story, with FY2025 revenue of $606M growing 66.7% year over year on the back of ARIKAYCE and the newly approved BRINSUPRI (brensocatib, approved in the US in August 2025 for non-cystic-fibrosis bronchiectasis). The revenue trajectory is the bull case: from $188M in FY2021 to $606M in FY2025, the top line has more than tripled in four years, and a second commercial product plus EU approval of BRINSUPRI broadens the runway.

The balance sheet of the income statement, however, is brutal. The company lost $1.28B in FY2025 (net margin -210.5%), burned $935M in operating cash, spent $771M on R&D, and carries an accumulated deficit of $5.64B. Stockholders' equity of $739M and cash of $510M, against an operating loss of $1.25B, mean Insmed is structurally dependent on capital markets — management itself states cash funds operations for 'at least the next 12 months,' implying ongoing dilution (shares already grew 19.1% in the year). Gross margin is only 18.5%, unusually thin for a specialty pharma, leaving little operating leverage even as revenue scales.